| abstract |
The present invention relates to thiazolidinedione analogs that are useful for treating diseases mediated by metabolic inflammation, such as diabetes. The invention also relates to insulin sensitizers having reduced binding and activation of the nuclear transcription factor PPARĪ³. In one aspect, the present invention provides a pharmaceutical composition useful for treating diseases mediated by metabolic inflammation comprising a compound of formula I or a pharmaceutically acceptable salt of said compound. Another aspect of the invention provides a method of treating a disease mediated by metabolic inflammation by administering a compound of formula I to a patient. |